The AGE inhibitor pyridoxamine inhibits lipemia and development of renal and vascular disease in Zucker obese rats

Kidney International

Volumn 63, Issue 6, 2003, Pages 2123-2133

  Alderson, Nathan L ^a   Chachich, Mark E ^a   Youssef, Nancy N ^a   Beattie, Robert J ^a   Nachtigal, Maurice ^a   Thorpe, Suzanne R ^a   Baynes, John W ^a,b  

^a UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Advanced glycation end product (AGE); Advanced lipoxidation end product (ALE); Dyslipidemia; Hyperlipidemia; Hypertension; Nephropathy; Pyridoxamine; Zucker rat

Indexed keywords

4 HYDROXYNONENAL; ADVANCED GLYCATION END PRODUCT INHIBITOR; ADVANCED GLYCATION END PRODUCT RECEPTOR; ALBUMIN; ANTILIPEMIC AGENT; CHOLESTEROL; CREATININE; LYSINE; MALONALDEHYDE; PENTOSIDINE; PROTEIN; PYRIDORIN; PYRIDOXAMINE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTICLE; CHEMICAL MODIFICATION; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORRELATION ANALYSIS; CREATININE CLEARANCE; DIABETIC NEPHROPATHY; FEMALE; GAS CHROMATOGRAPHY; GLUCOSE METABOLISM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; KIDNEY DISEASE; LIPID OXIDATION; MASS SPECTROMETRY; MICROSCOPY; NONHUMAN; OBESITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RAT; STATISTICAL SIGNIFICANCE; STREPTOZOCIN DIABETES; THICKNESS; TRIACYLGLYCEROL BLOOD LEVEL; VASCULAR DISEASE;

EID: 0038527321     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.2003.00027.x     Document Type: Article

References (47)

1. THORPE SR, BAYNES JW: Role of the Maillard reaction in diabetes mellitus and diseases of aging. Drugs Aging 9:69-77, 1996
2. BAYNES JW, THORPE SR: Glycation and advanced glycation reactions, in Diabetes in the New Millennium, edited by TURTLE JR, KANEKO T, OSATO S, Sydney, Endocrinology and Diabetes Research Foundation, 1999, pp 337-350
3. ULRICH P, CERAMI A: Protein glycation, diabetes, and aging. Recent Prog Horm Res 56:1-21, 2001
4. KHALIFAH RG, BAYNES JW, HUDSON BG: Amadorins: Novel post-Amadori inhibitors of advanced glycation reactions. Biochem Biophys Res Commun 257:251-258, 1999
5. DEGENHARDT TP, ALDERSON NL, ARRINGTON DD, et al: Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat. Kidney Int 61:939-950, 2002
6. ONORATO JM, JENKINS AJ, THORPE SR, BAYNES JW: Pyridoxamine, an inhibitor of advanced glycation reactions, also inhibits advanced lipoxidation reactions. J Biol Chem 275:21177-21184, 2000
7. ε-(carboxymethyl)lysine, is a product of both lipid peroxidation and glycoxidation reactions. J Biol Chem 271:9982-9986, 1996
8. KASISKE BL, O'DONNELL MP, KEANE WF: The Zucker rat model of obesity, insulin resistance, hyperlipidemia, and renal injury. Hypertension 19(Suppl 1): I110-I115, 1992
9. STEVENSON FT, KAYSEN GA: Hyperlipidemia and renal disease: The use of animal models in understanding pathophysiology and approaches to treatment. Wien Klin Wochenschr 111:307-314, 1999
10. HANSEN BC: The metabolic syndrome X. Ann N Y Acad Sci 892:1-24, 1999
11. TIMAR O, SESTIER F, LEVY E: Metabolic syndrome X: A review. Can J Cardiol 16:779-789, 2000
12. VAN ZWIETEN PA, KAM KL, PIJL AJ, et al: Hypertensive diabetic rats in pharmacological studies. Pharmacol Res 33:95-105, 1996
13. PETERSON RG: The Zucker diabetic fatty (ZDF) rat, in Lessons from Animal Diabetes, Vol. V, edited by SHAFRIR E, London, Smith Gordon, 1995, pp 225-230
14. 6 vitamins and pyridoxic acid in plasma, tissues and urine using high performance liquid chromatography. Nutr Res 9:259-272, 1989
15. BAUER WC, ROSENBERG BF: A quantitative study of glomerular enlargement in children with tetralogy of Fallot. Am J Pathol 37:695-712, 1960
16. DYER DG, DUNN JA, THORPE SR, et al: Accumulation of Maillard reaction products in skin collagen in diabetes and aging. J Clin Invest 91:2463-2469, 1993
17. REQUENA JR, FU M-X, AHMED MU, et al: Quantitation of malondialdehyde and 4-hydroxynonenal adducts to lysine residues in native and oxidized human low density lipoprotein. Biochem J 322:317-325, 1997
18. SCHLEICHER E, WIELAND OH: Kinetic analysis of glycation as a tool for assessing the half-life of proteins. Biochim Biophys Acta 884:199-205, 1986
19. PAMPLONA R, PORTERO-OTIN M, RUIZ C, et al: Thyroid status modulates glycoxidative and lipoxidative modification of tissue proteins. Free Radic Biol Med 27:901-910, 1999
20. STEGEMANN H, STALDER K: Determination of hydroxyproline. Clin Chim Acta 18:267-273, 1967
21. KASISKE BL, CLEARY MP, O'DONNELL MP, KEANE WF: Effects of genetic obesity on renal structure and function in the Zucker rat. J Lab Clin Med 106:598-604, 1985
22. FRYE EB, DEGENHARDT TP, THORPE SR, et al: Role of the Maillard reaction in aging of tissue proteins: age-dependent increase in imidazolium crosslinks in human lens protein. J Biol Chem 273:18714-18719, 1998
23. BAYNES JW, THORPE SR: Glycoxidation and lipoxidation in atherogenesis. Free Radic Biol Med 28:1708-1716, 2000
24. SAYRE LM, ARORA PK, IYER RS, SALOMON RG: Pyrrole formation from 4-hydroxynonenal and primary amines. Chem Res Toxicol 6:19-22, 1993
25. ATTMAN P-O, ALAUPOVIC P, SAMUELSSON O: Lipoprotein abnormalities as a risk factor for progressive nondiabetic renal disease. Kidney Int 56(Suppl 71):S14-S17, 1999
26. KEANE WF: The role of lipids in renal disease: future challenges. Kidney Int 57(Suppl 75):S27-S31, 2000
27. SASATOMI Y, TADA M, UESUGI N, et al: Obesity associated with hypertension or hyperlipidemia accelerates renal damage. Pathobiol 69:113-118, 2001
28. MADDOX DA, ALAVl FK, SANTELLA RN, ZAWADA ET, JR: Prevention of obesity-linked renal disease: Age-dependent effects of dietary food restriction. Kidney Int 62:208-219, 2002
29. BOOTH AA, KHALIFAH RG, HUDSON BG: Thiamine pyrophosphate and pyridoxamine inhibit the formation of antigenic advanced glycation end-products: Comparison with aminoguanidine. Biochem Biophys Res Commun 220:113-119, 1996
30. BOOTH AA, KHALIFAH RG, TODD P, HUDSON BG: In vitro kinetic studies of formation of antigenic advanced glycation end products (AGEs): Novel inhibition of post-Amadori glycation pathways. J Biol Chem 272:5430-5437, 1997
31. VOZIYAN PA, METZ TO, BAYNES JW, HUDSON BG: Pyridoxamine inhibits chemical modification of proteins by scavenging carbonyl intermediates of carbohydrate and lipid degradation. J Biol Chem 277:3397-3403, 2002
32. SCHMIDT AM, YAN SD, YAN SF, STERN DM: The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J Clin Invest 108:949-955, 2001
33. ε-(hexanoyl)lysine in protein exposed to lipid hydroperoxide: A plausible marker for lipid hydroperoxide-derived protein modification. J Biol Chem 274:20406-20414, 1999
34. ODA H, KEANE WF: Lipids in progress of renal disease. Kidney Int 52(Suppl 2):S36-S38, 1997
35. SMULDERS YM, VAN EEDEN AE, STEHOUWER CD, et al: Can reduction in hypertriglyceridaemia slow progression of microalbuminuria in patients with non-insulin-dependent diabetes mellitus? Eur J Clin Invest 27:997-1002, 1997
36. LAVAUD S, MICHEL O, SASSY-PRIGENT C, et al: Early influx of glomerual macrophages precedes glomerulosclerosis in the obese Zucker rat model. J Am Soc Nephrol 7:2604-2615, 1993
37. KASISKE BL, O'DONNELL MP, CLEARY MP, KEANE WF: Treatment of hyperlipidemia reduces glomerular injury in obese Zucker rats. Kidney Int 33:667-672, 1988
38. O'DONNELL MP, KASISKE BL, KIM Y, et al: Lovastatin retards the progression of established glomerular disease in obese Zucker rats. Am J Kidney Dis 22:83-89, 1993
39. MICHEL O, HEUDES D, LAMARRE I, et al: Reduction of insulin and triglycerides delays glomerulosclerosis in obese Zucker rats. Kidney Int 52:1532-1542, 1997
40. PRICE DL, RHETT PM, THORPE SR, BAYNES JW: Chelating activity of AGE inhibitors. J Biol Chem 276:48967-48972, 2001
41. MIYATA T, VAN YPERSELE DE STRIHOU C, KUROKAWA K, BAYNES JW: Alterations in nonenzymatic biochemistry in uremia: Origin and significance of "carbonyl stress" in long-term uremic complications. Kidney Int 55:389-399, 1999
42. GUIJARRO C, KEANE WF: Lipid abnormalities and changes in plasma proteins in glomerular diseases and chronic renal failure. Curr Opin Nephrol Hypertens 2:372-379, 1993
43. SAITO T: Abnormal lipid metabolism in renal disorders. Tohoku J Exp Med 181:321-337, 1997
44. KURTZ TW, MORRIS RC, PERSHADSINGH HA: The fatty Zucker rat as a genetic model of obesity and hypertension. Hypertension 13:806-901, 1989
45. WIENER J, LOUD AV, GIACOMELLI F, ANVERSA P: Morphometric analysis of hypertension-induced hypertrophy of rat thoracic aorta. Am J Pathol 88:619-633, 1977
46. KOWALA MC, CUENOUD HF, JORIS I, MAJNO G: Cellular changes during hypertension: A quantitative study of rat aorta. Exp Mol Pathol 45:323-335, 1986
47. JIANG ZY, LIN Y-W, CLEMONT A, et al: Characterization of selective resistance to insulin signaling in the vasculature of obese Zucker (fa/fa) rats. J Clin Invest 104:447-457, 1999